A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anaplastic Thyroid Cancer
- Thyroid Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Patients who fulfill eligibility criteria will be entered into the trial to receive ML0N128. The participant will be given a study drug-dosing diary for each treatment cycle. After the screening procedures confirm participation in the research study. - MLN0128 - Fixed doses daily per treatment cycle...
Patients who fulfill eligibility criteria will be entered into the trial to receive ML0N128. The participant will be given a study drug-dosing diary for each treatment cycle. After the screening procedures confirm participation in the research study. - MLN0128 - Fixed doses daily per treatment cycle The treatment cycles will continue until the participants disease gets worse or is taken off treatment for any other reason.Once treatment has been discontinued the investigators will check on the participants health status by phone for the rest of their life.
Tracking Information
- NCT #
- NCT02244463
- Collaborators
- Millennium Pharmaceuticals, Inc.
- Investigators
- Principal Investigator: Jochen Lorch, MD. PhD Dana-Farber Cancer Institute
Get Well Soon